GlassScriptPhysician profile
Ninfa Recinto
NPI 1760968382
$4,416.75
in general payments reported to CMS, 2019-2025
10 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $244 · 2023: $2,909 · 2024: $802 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613 · Travel and Lodging: $1,479 · Consulting Fee: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.05 |
| Travel and Lodging | $1,479.00 |
| Consulting Fee | $810.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $3,134.23 | 2021-2023 | Korsuva, Veltassa |
| Fresenius USA Marketing, INC. | $277.96 | 2022-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $274.61 | 2024 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $236.22 | 2024 | |
| Calliditas Therapeutics US INC. | $136.69 | 2024 | |
| Akebia Therapeutics INC | $136.30 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $121.38 | 2025 | Terlivaz |
| Amgen INC. | $54.36 | 2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $28.52 | 2024 | |
| Medline Industries LP | $16.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ninfa Recinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.